PMID- 38078453
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240124
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 19
IP  - 1
DP  - 2024 Jan-May
TI  - Comparison of teneligliptin and other gliptin-based regimens in addressing 
      insulin resistance and glycemic control in type 2 diabetic patients: a 
      cross-sectional study.
PG  - 81-87
LID - 10.1080/17446651.2023.2290486 [doi]
AB  - INTRODUCTION: The objective of this study was to compare the effects of 
      teneligliptin-based regimens and other gliptin-based regimens with respect to 
      insulin resistance and glycemic control in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: We enrolled T2DM subjects, inadequately controlled with 
      metformin and glimepiride and taking one of the gliptins, and divided them into 
      two groups, i.e. group 1 (teneligliptin-based regimens) and group 2 (other 
      gliptin-based regimens). Fasting plasma insulin, adiponectin levels, homeostatic 
      model assessment for insulin resistance (HOMA-IR), glycated hemoglobin (HbA1c), 
      and fasting blood glucose (FBG) were measured and compared. Costs of different 
      gliptins were noted, and mean cost of per day therapy was compared. RESULTS: 
      Eighty-six subjects participated in this study (43 each in group 1 and group 2). 
      No significant differences were observed in FBG, HbA1c, insulin levels, and 
      HOMA-IR, but the trend was in favor of teneligliptin-based regimens. A 
      significantly higher number of subjects achieved HbA1c target in group 1 
      (P < 0.001). Teneligliptin had significantly lower cost of per day therapy as 
      compared to other dipeptidyl peptidase-4 inhibitors. CONCLUSION: Teneligliptin 
      seems to be cost-effective and safer option in T2DM subjects who were not 
      adequately controlled with metformin and sulfonylureas. However, further 
      prospective studies are needed.
FAU - Singh, Harmanjit
AU  - Singh H
AD  - Department of Pharmacology, Government Medical College & Hospital, Chandigarh, 
      India.
FAU - Rohilla, Ravi
AU  - Rohilla R
AD  - Department of Community Medicine, Government Medical College & Hospital, 
      Chandigarh, India.
FAU - Jaswal, Shivani
AU  - Jaswal S
AD  - Department of Biochemistry, Government Medical College & Hospital, Chandigarh, 
      India.
FAU - Singla, Mandeep
AU  - Singla M
AD  - Department of General Medicine, Government Medical College & Hospital, 
      Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20240101
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 
      (3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 9100L32L2N (Metformin)
RN  - 0 (Insulins)
SB  - IM
MH  - Humans
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - *Diabetes Mellitus, Type 2
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Cross-Sectional Studies
MH  - Glycated Hemoglobin
MH  - *Insulin Resistance
MH  - Glycemic Control
MH  - Blood Glucose
MH  - *Metformin/therapeutic use
MH  - *Insulins
OTO - NOTNLM
OT  - HbA1c
OT  - T2DM
OT  - insulin resistance
OT  - sitagliptin
OT  - teneligliptin
EDAT- 2023/12/11 12:42
MHDA- 2024/01/03 09:44
CRDT- 2023/12/11 07:59
PHST- 2024/01/03 09:44 [medline]
PHST- 2023/12/11 12:42 [pubmed]
PHST- 2023/12/11 07:59 [entrez]
AID - 10.1080/17446651.2023.2290486 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2024 Jan-May;19(1):81-87. doi: 
      10.1080/17446651.2023.2290486. Epub 2024 Jan 1.